Moderna

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna Inc. (MRNA) is a clinical-stage biotechnology company based in Cambridge, Massachusetts. Its main focus is on the development of therapies based on messenger ribonucleic acid (mRNA). Moderna began public trading on December 7, 2018, after raising over $604 million in an initial public offering (IPO). Moderna shares opened with an initial IPO price of $23.00 and peaked at an intraday high of $122.38 on January 13, 2021, representing a 428% increase. On March 2, 2021, Moderna's market capitalization crossed the $50 billion mark for the first time. Moderna shares have more than doubled in the second quarter of 2021 and the company is now valued at more than triple its market capitalization at IPO. Moderna's success is largely attributed to a successful COVID-19 vaccine developed in response to the ongoing pandemic, but also to its strong pipeline of RNA-based therapies for cancer, rare diseases, and cardiovascular, metabolic, and infectious diseases. The company hopes to continue building on its successes and is currently launching clinical studies that explore a variety of next-generation mRNA therapies.

To develop treatments for diseases with unmet medical need and deliver life-changing impact to patients and their families.

Our vision is for Moderna to be the best biotechnology company in the world, achieving high clinical and commercial success.